LEADER 04340nam  2201201z- 450 
001 9910595070803321
005 20231214133143.0
035   $a(CKB)5680000000080822
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92074
035   $a(EXLCZ)995680000000080822
100   $a20202209d2022      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDiagnostic or Therapeutic Strategies for Pregnancy Complications
210   $aBasel$cMDPI Books$d2022
215   $a1 electronic resource (238 p.)
311   $a3-0365-4877-7 
311   $a3-0365-4878-5 
330   $aIt is well known that pregnancy complications, including preeclampsia, preterm birth, stillbirth, and intrauterine growth restriction affect over 12% of all pregnancies worldwide. These complications negatively impact both maternal and neonatal health and have short- and long-term effects such as an increased risk of neurodevelopmental and cardiovascular diseases. Over the past decade, numerous groups have investigated the use of new and/or existing drugs to either prolong gestation, such as in cases of threatened preterm labour; alleviate hypertension in preeclampsia; or promote adequate blood flow and nutrient delivery to the placenta to facilitate growth in IUGR. The overarching goal has been to promote healthier pregnancies and neonatal health, but it has been difficult to translate this work into the clinical setting, with problems in terms of drug delivery, specificity, and importantly, the early diagnostic capacities for complications in pregnancy. This book focuses on the early detection, potential novel therapeutic targets, risk factors, maternal outcomes, and long-term consequences of this critical problem.
606   $aMedicine$2bicssc
610   $aultrasonography
610   $aelastography
610   $auterine cervix
610   $aterm pregnancy
610   $aparturition
610   $agenotyping
610   $apreeclampsia
610   $aMMP-9
610   $aMMP-2
610   $aSNPs
610   $atocolytic
610   $apreterm birth
610   $apreterm labor
610   $aneonate
610   $aprematurity
610   $apregnancy
610   $atherapeutic
610   $aprogesterone
610   $afetus
610   $asex as a biological variable
610   $asex differences
610   $apregnancy complications
610   $aplacenta
610   $aprenatal diagnosis
610   $afetal growth restriction
610   $amiscarriage
610   $achorio-deciduitis
610   $agrade
610   $aamnionitis
610   $aacute histologic chorioamnionitis
610   $aintra-amniotic inflammatory response
610   $abeta-blocker
610   $aendothelial dysfunction
610   $acardiovascular disease
610   $apregnancy loss
610   $aimmunology
610   $avascular endothelial growth factor
610   $agalectin-9
610   $ainterleukin-4
610   $aproteomics
610   $aurine
610   $abiomarkers
610   $aIBP4
610   $aSHBG
610   $aRPL
610   $aNK cells
610   $asildenafil
610   $aPDE5A
610   $aVEGF-A
610   $aangiotensin
610   $ainfant
610   $anewborn
610   $afemale
610   $aabruptio placentae
610   $aApgar score
610   $apregnant women
610   $agestational age
610   $aIL-1 blockade
610   $aanakinra
610   $acanakinumab
610   $ahuman
610   $ainflammation
610   $afetal growth restriction (FGR)
610   $aintra-uterine growth restriction (IUGR)
610   $aSPINT1
610   $aHAI-1
610   $astillbirth
610   $aplacental insufficiency
610   $ahistopathology
610   $acardiovascular risk
610   $apostpartum screening
615  7$aMedicine
700   $aHeazell$b Alexander$4edt$01328470
702   $aGirard$b Sylvie$4edt
702   $aHeazell$b Alexander$4oth
702   $aGirard$b Sylvie$4oth
906   $aBOOK
912   $a9910595070803321
996   $aDiagnostic or Therapeutic Strategies for Pregnancy Complications$93038575
997   $aUNINA